Prospera Financial Services Inc Decreases Stake in Becton, Dickinson and Company $BDX

Prospera Financial Services Inc cut its holdings in shares of Becton, Dickinson and Company (NYSE:BDX) by 50.7% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 2,927 shares of the medical instruments supplier’s stock after selling 3,009 shares during the quarter. Prospera Financial Services Inc’s holdings in Becton, Dickinson and Company were worth $549,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also recently modified their holdings of the business. Brighton Jones LLC lifted its position in shares of Becton, Dickinson and Company by 98.2% during the fourth quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier’s stock worth $401,000 after acquiring an additional 877 shares in the last quarter. Empowered Funds LLC raised its position in shares of Becton, Dickinson and Company by 20.4% in the first quarter. Empowered Funds LLC now owns 7,977 shares of the medical instruments supplier’s stock worth $1,827,000 after buying an additional 1,354 shares in the last quarter. Stratos Wealth Partners LTD. boosted its stake in Becton, Dickinson and Company by 0.5% during the second quarter. Stratos Wealth Partners LTD. now owns 16,040 shares of the medical instruments supplier’s stock valued at $2,763,000 after buying an additional 81 shares during the period. United Bank grew its position in Becton, Dickinson and Company by 23.9% during the second quarter. United Bank now owns 5,149 shares of the medical instruments supplier’s stock worth $887,000 after buying an additional 993 shares in the last quarter. Finally, Chicago Partners Investment Group LLC increased its stake in Becton, Dickinson and Company by 15.3% in the 2nd quarter. Chicago Partners Investment Group LLC now owns 1,807 shares of the medical instruments supplier’s stock worth $330,000 after acquiring an additional 240 shares during the last quarter. Hedge funds and other institutional investors own 86.97% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on the stock. Royal Bank Of Canada set a $172.00 target price on shares of Becton, Dickinson and Company in a research note on Tuesday, February 10th. Wells Fargo & Company lowered their target price on Becton, Dickinson and Company from $184.00 to $157.00 and set an “equal weight” rating for the company in a research note on Tuesday, February 10th. Zacks Research cut Becton, Dickinson and Company from a “hold” rating to a “strong sell” rating in a research note on Wednesday, February 11th. Morgan Stanley increased their price objective on Becton, Dickinson and Company from $197.00 to $210.00 and gave the company an “overweight” rating in a research note on Tuesday, December 2nd. Finally, JPMorgan Chase & Co. decreased their target price on shares of Becton, Dickinson and Company from $190.00 to $175.00 and set a “neutral” rating on the stock in a research note on Tuesday, February 10th. Five investment analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Becton, Dickinson and Company has an average rating of “Hold” and a consensus target price of $195.46.

Becton, Dickinson and Company Stock Performance

Shares of Becton, Dickinson and Company stock opened at $175.95 on Tuesday. Becton, Dickinson and Company has a 12 month low of $127.59 and a 12 month high of $185.02. The firm has a market capitalization of $50.10 billion, a P/E ratio of 28.70, a P/E/G ratio of 2.30 and a beta of 0.25. The company has a current ratio of 1.05, a quick ratio of 0.58 and a debt-to-equity ratio of 0.67. The business has a fifty day simple moving average of $198.55 and a two-hundred day simple moving average of $192.32.

Becton, Dickinson and Company (NYSE:BDX) last issued its quarterly earnings results on Monday, February 9th. The medical instruments supplier reported $2.91 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.81 by $0.10. Becton, Dickinson and Company had a net margin of 8.01% and a return on equity of 15.76%. The company had revenue of $5.25 billion during the quarter, compared to analyst estimates of $5.15 billion. During the same period last year, the business earned $3.43 EPS. Becton, Dickinson and Company’s quarterly revenue was up 1.6% compared to the same quarter last year. Becton, Dickinson and Company has set its FY 2026 guidance at 12.350-12.650 EPS. On average, equities analysts forecast that Becton, Dickinson and Company will post 14.43 earnings per share for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 31st. Investors of record on Tuesday, March 10th will be given a dividend of $1.05 per share. This represents a $4.20 dividend on an annualized basis and a yield of 2.4%. The ex-dividend date of this dividend is Tuesday, March 10th. Becton, Dickinson and Company’s dividend payout ratio (DPR) is 68.52%.

Becton, Dickinson and Company announced that its board has authorized a share repurchase plan on Tuesday, January 27th that permits the company to buyback $10.00 million in shares. This buyback authorization permits the medical instruments supplier to purchase up to 0% of its stock through open market purchases. Stock buyback plans are often an indication that the company’s board believes its shares are undervalued.

Insider Transactions at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, EVP Michael David Garrison sold 1,610 shares of Becton, Dickinson and Company stock in a transaction on Thursday, January 15th. The stock was sold at an average price of $207.46, for a total transaction of $334,010.60. Following the completion of the transaction, the executive vice president owned 12,095 shares in the company, valued at approximately $2,509,228.70. The trade was a 11.75% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders sold a total of 2,463 shares of company stock worth $501,530 in the last three months. 0.40% of the stock is currently owned by insiders.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.